Evidence map›Paper›PMID 35117354›Full record

ArticleTranslational cancer research2020

AT-rich interactive domain1A determines sensitivity to oxaliplatin in gastric cancer cells.

Qing Liu, Qing-Qing Weng, Song-Fei Shen, Tao Jiang, Zhang-Chi Pan, Meng-Xin Lin, Yan-Qin Lan, Yao Wang, Qiang Chen, Chun-Mei Shi

Abstract read
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qing LiuDepartment of Oncology, Union Medical College Hospital, Fujian Medical University, Fuzhou, China.
Qing-Qing WengDepartment of Oncology, First Hospital of Putian City, Putian, China.
Song-Fei ShenDepartment of Oncology, Union Medical College Hospital, Fujian Medical University, Fuzhou, China.
Tao JiangDepartment of Oncology, Union Medical College Hospital, Fujian Medical University, Fuzhou, China.
Zhang-Chi PanDepartment of Oncology, Union Medical College Hospital, Fujian Medical University, Fuzhou, China.
Meng-Xin LinDepartment of Oncology, Union Medical College Hospital, Fujian Medical University, Fuzhou, China.
Yan-Qin LanDepartment of Oncology, Union Medical College Hospital, Fujian Medical University, Fuzhou, China.
Yao WangDepartment of Oncology, Union Medical College Hospital, Fujian Medical University, Fuzhou, China.
Qiang ChenDepartment of Oncology, Union Medical College Hospital, Fujian Medical University, Fuzhou, China.
Chun-Mei ShiDepartment of Oncology, Union Medical College Hospital, Fujian Medical University, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastric cancer is a highly heterogeneous disease and its traditional histopathological classification is difficult to meet clinical needs. Oxaliplatin is an antitumor drug with high efficiency and low toxicity. Therefore, the insensitivity or secondary drug resistance of oxaliplatin to gastric cancer is vital for tumor progression. The aim of this study was to investigate the sensitivity of gastric cancer cells to oxaliplatin after

methodsMGC-803 and AGS cells were selected as gastric cancer cells for study. ARID1A protein and mRNA expression was detected by Western blot and quantitative reverse-transcription PCR (qRT-PCR). The short hairpin RNA (shRNA) fragment of

resultsThe proliferation of gastric cancer cells was promoted by

conclusions

Indexed as

AT-rich interactive domain1A (ARID1A)gastric canceroxaliplatin

Identifiers

PMID35117354
PMCPMC8798539

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.